13 results about "Diethyl fumarate" patented technology

The invention discloses a lithium titanate battery, and relates to the technical field of batteries. The battery comprises a positive electrode, a negative electrode, an electrolyte and a diaphragm, and an addition product synthesized by dimethyl fumarate and benzidine according to a specific molar ratio is added into the electrolyte as a viscosity modifier, so that the viscosity increasing trend of the electrolyte at a low temperature is effectively reduced, and the migration rate of lithium ions is improved. And the electrolyte also comprises a lithium salt, an organic solvent and an auxiliary additive, so that the low-temperature performance and the cycling stability of the battery are favorably optimized. A positive active material is one or more of lithium iron phosphate, lithium manganate, lithium cobalt oxide or nickel manganese cobalt ternary materials, a negative active material is lithium titanate, and additives such as lithium nitrate and fluoroethylene carbonate are further combined, so that the capacity retention ratio and the charge-discharge efficiency of the battery in an extreme low-temperature environment of-40 DEG C are remarkably improved. The lithium titanate battery provided by the invention has excellent low-temperature adaptability, safety and long cycle life, and is applicable to power batteries and energy storage systems in alpine regions.

The present disclosure provides methods of treating multiple sclerosis (MS) using Compound 1 represented by the following structure, or a pharmaceutically acceptable salt thereof, in combination with dihydroxymethyl fumarate (DRF).

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The invention provides a thermal expansion material, a resin liquid bridge plug and a deep shale gas shaft pressure-bearing plugging method. The thermal expansion material comprises a combination of any two or three of oxidative polymerization grafted 3-alkylthiophene modified thermal expansion microspheres, glycidyl methacrylate grafted modified thermal expansion microspheres and cinnamyl nitrile and diethyl fumarate cross-linked thermal expansion core-shell microspheres; by taking the total weight of the thermal expansion material as 100%, when the thermal expansion material comprises an oxidative polymerization grafted 3-alkylthiophene modified thermal expansion microsphere, a glycidyl methacrylate grafted modified thermal expansion microsphere and a cinnamyl nitrile and diethyl fumarate cross-linked thermal expansion core-shell microsphere, the contents of the three are respectively 15-55%, 25-75% and 30-65%. The thermal expansion material has good compatibility with resin liquid bridge plugs, can be uniformly dispersed in resin, does not agglomerate or settle, and can effectively inhibit the shrinkage of the resin through heat release expansion after solidification.

The invention discloses an application of a small molecule compound covalently bound with GSDMD in preparation of a pyroptosis inhibitor. Through deep research, a novel compound AF-966 / 00547018, called C6 for short, which can specifically target GSDMD protein and effectively inhibit the pore-forming activity of the GSDMD protein is screened, and the structure of the compound AF-966 / 00547018 is shown in the specification. Compared with reported pyroptosis inhibitors such as disulfiram, dimethyl fumarate and Necrosulfenamide (NSA), the C6 shows higher activity of inhibiting the pyroptosis of the cells, and the C6 shows higher activity of inhibiting the pyroptosis of the cells.

The invention relates to the technical field of medicines, in particular to application of dimethyl fumarate in promoting proliferation of amniotic fluid stem cells and application of dimethyl fumarate in promoting proliferation of amniotic fluid stem cells. The invention discloses an application of dimethyl fumarate as an NRF2 expression promoter. The administration concentration of the dimethyl fumarate is 2.5 to 10 M; the dimethyl fumarate promotes NRF2 expression, protects the amniotic fluid stem cells, reduces oxidative damage and accelerates proliferation of the amniotic fluid stem cells, the cell culture time is shortened to 72 hours, and the DMF monovalent value is 1 / 40 of that of a growth factor.

The invention discloses application of dimethyl fumarate in preparation of a medicine for preventing and / or treating skeletal muscle atrophy, and belongs to the field of medicine. It is proved for the first time that DMF can effectively relieve related symptoms of skeletal muscle atrophy caused by cancer cachexia, and a new thought is provided for treatment of skeletal muscle atrophy. The DMF can relieve skeletal muscle atrophy by reducing mitochondrial damage and improving mitochondrial homeostasis imbalance, and the potential mechanism of the DMF is possibly related to the regulation of HIF1alpha, mTOR and other pathways. In addition, DMF can improve cancer cachexia skeletal muscle atrophy and does not inhibit tumor growth, which indicates that DMF directly acts on skeletal muscle instead of tumor. Due to the common end characteristic of mitochondrial homeostasis imbalance and the like in amyotrophy caused by different causes (such as aging and drug toxicity), the adjusting effect of DMF on homeostasis in skeletal muscle can be expanded to be used for preventing and treating other types of amyotrophy, including amyotrophy caused by aging, glucocorticoid, chemotherapy drugs and the like. The invention provides an application basis for preventing and treating skeletal muscle atrophy by DMF.

The application discloses a kind of detection methods of dimethyl fumarate in food, it is related to chemical detection analysis technical field, comprising the following steps: S1, based on standard solution sample configuration standard curve;S2, the formula of purifying tube is selected and three representative samples, and based on purification scheme, sample is purified;S3, set two standard curve concentration points, carry out multiple sample data acquisition;S4, to three samples are detected in parallel double sample, and the detection limit level of sample, 1 times quantification limit level, 2 times quantification limit level and 5 times quantification limit level are 6 parallel standard addition test, based on experimental data is verified.The application makes that the dosage of organic reagent is saved about 80%, operation time is saved about 75%, the addition of internal standard DMM effectively calibrates the influence that target DMF changes with time and matrix interference, guarantees the result accuracy, while operation process is simple, to reduce the requirement of laboratory to personnel operation skill.

Examination of a test sample to determine the succination level of test sample is described. Examination can be via protein hydrolysis in total succination determination or via enzymatic digestion of isolated proteins and determination of the presence or quantity of modified peptides. The methods can be utilized for determination of excessive succination of lymph system proteins, which can be utilized in prevention or early detection of autoimmune disorders. Methods can be utilized for test samples of subjects under treatment with dimethyl fumarate suffering from an autoimmune disorder. Methods can be utilized as a determination that treatment of the subject with DMF should be slowed or stopped.

The application discloses a lithium titanate battery and relates to the technical field of batteries.The battery comprises a positive electrode, a negative electrode, an electrolyte and a diaphragm, wherein the electrolyte is added with an adduct synthesized from dimethyl fumarate and benzidine in a specific molar ratio as a viscosity regulator, which effectively reduces the viscosity growth trend of the electrolyte at low temperature and improves the migration rate of lithium ions.The electrolyte further comprises lithium salt, organic solvent and auxiliary additives, which are beneficial to optimizing the low-temperature performance and cycle stability of the battery.The positive electrode active material is one or more of lithium iron phosphate, lithium manganate, lithium cobaltate or nickel-manganese-cobalt ternary material, and the negative electrode active material is lithium titanate, which is further combined with additives such as lithium nitrate and fluoroethylene carbonate, so that the capacity retention rate and charge-discharge efficiency of the battery at an extreme low temperature environment of-40 DEG C are significantly improved.The lithium titanate battery provided by the application has excellent low-temperature adaptability, safety and long cycle life, and is suitable for high-cold-area power batteries and energy storage system applications.

Examination of a test sample to determine the presence or quantity of succination of proteins is described. Examination can be via protein hydrolysis in total succination determination or via enzymatic digestion of isolated proteins and determination of the presence or quantity of modified peptides. The methods can be utilized for determination of excessive succination of lymph system proteins, which can be utilized in prevention or early detection of lymphopenia. Methods can be utilized for test samples of subjects under treatment with dimethyl fumarate suffering from multiple sclerosis. Methods can be utilized as a determination that treatment of the subject with DMF should be slowed or stopped.

The present disclosure provides methods and compositions for improving cell viability, mitochondrial function and / or frataxin expression or treating Friedreich's ataxia (FRDA) comprising two or more of monomethyl fumarate (MMF) or a MMF prodrug such as dimethyl fumarate (DMF), nicotinamide (NAM), idebenone (IDB) and nitisinone (NTS).

The application provides a low-sensitization aspartic acid ester resin composite and a preparation process thereof, and relates to the technical field of aspartic acid resin. The aspartic acid ester resin composite comprises the following raw material components: (A) polyaspartic acid resin, (B) monoamine maleate adduct, and (C) diethyl fumarate and / or diethyl maleate, which accounts for no more than 0.5% of the weight of the aspartic acid ester resin composite. The aspartic acid ester resin composite has the characteristics that the weight percentage of diethyl fumarate and diethyl maleate is low, no sensitization is caused to human body, and the curing performance is close to that of the existing polyaspartic acid resin.